NEW YORK (GenomeWeb News) – Affymetrix today said that that it has penned a five-year gene-expression collaboration with the Peter MacCallum Cancer Centre in Australia.
 
Terms of the agreement call for Peter Mac researchers to use Affymetrix GeneChip technology for translational research projects. The first studies will cover ovarian cancer and carcinoma of unknown primaries.
 
Millennium Science will supply Peter Mac with Affy’s technology and provide technical support.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.